Most Supplement Companies Skip the RCT. Here’s Why the Few That Don’t Often Get It Wrong The industry’s uncomfortable truth The global dietary supplement market is worth hundreds of billions of dollars.[1] Brands make claims about energy, cognition, immunity, and...
Neurona Therapeutics' rezanecel demonstrates durable seizure reduction past the one-year mark in drug-resistant mesial temporal lobe epilepsy at the AAN Annual Meeting, Gilead Sciences and Arcus Biosciences' TIGIT inhibitor domvanalimab fails its pivotal Phase 3 lung...
Panthera Biopartners Expands European Footprint with Acquisition of Hungary’s Leading Clinical Research Organisation, OEC Strategic acquisition marks the first step in Panthera’s European expansion, strengthening its global competitiveness Panthera Biopartners...
Revolution Medicines' daraxonrasib nearly doubles overall survival in previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial, Travere Therapeutics' Filspari receives FDA approval as the first-ever treatment for focal segmental...
The daraxonrasib pancreatic cancer trial results announced on 13 April 2026 represent what many in the oncology community are calling a landmark moment for one of medicine's most stubborn and lethal diseases. Revolution Medicines, a late-stage clinical oncology...
It’s ironic that the rigid nature of clinical research depends on a largely fragile variable: people. Even the most promising therapy cannot succeed in development if the study evaluating it struggles to keep participants engaged. Recruiting patients is already a...
This week brought a remarkable series of clinical trial readouts spanning oncology, metabolic disease, neurology, and dermatology. Several pivotal datasets were released from late-stage and early-stage programmes, offering fresh hope for patients with conditions...
We work with hospitals, clinics, and health systems across the country every day. Over the past few years, one thing has become very clear: filling a specialist role is harder than it used to be, it takes longer, and the consequences of getting it wrong reach further...
Drug development is one of the most expensive and time-intensive innovation processes in the world. Estimates from the Tufts Center for the Study of Drug Development suggest that bringing a new drug to market can cost over $2.6 billion and take more than a decade of...
Medication non-adherence and dropout have long been labeled “known problems” in the clinical trial space. Yet despite years of tinkering with the formula, these challenges have only become “well-known problems.” Operational efficiencies and innovation, digital...
At the 2026 Congress of the European Society of Gynaecological Oncology (ESGO) in Copenhagen, Dr Gabriel Levin of the McGill University Health Centre will present Phase II data evaluating the investigational DNA therapy Elenagen in combination with gemcitabine for...
Dr Steven Cox, CEO of the research charity, Cardiac Risk in the Young (CRY) explains the key findings and importance of a seminal study (reviewing cardiac screening data collated over a 10 year period), published on 24 February 2026 in the Journal of the American...
Couples trying to conceive are bombarded with supplement recommendations. Scroll through any fertility forum and you'll find confident claims about CoQ10, vitamin D, and a dozen other compounds that supposedly hold the key to conception. Some of these recommendations...
Wouldn’t life be easier if someone was there to keep on top of chores around the house? That’s the idea behind Anavex Life Sciences’ experimental, once-daily pill blarcamesine, which is being tested in patients in the early stages of Alzheimer’s disease. This drug...
The next operational lessons for early-stage clinical trials in humans might not come from pharma but from a cattle ranch in Nebraska. While human clinical research debates decentralized trials, adaptive protocols, novel technologies, and new approaches to oversight,...
New research suggests that inflammatory and microstructural changes in a key brain reward region may differ between chronic depression and acute depressive symptoms, offering fresh insight into the biological mechanisms underlying the condition. In a large scale...
The Functional Gut Clinic (FGC), the UK’s leading provider of specialist gastrointestinal (GI) diagnostics, today announced the launch of its dedicated GI Clinical Trials establishing the organisation as the country’s first boutique, end‑to‑end clinical research...
Pharvaris Announces Positive Phase 3 Results for Deucrictibant as On Demand HAE Treatment Pharvaris has announced positive topline data from its global Phase 3 RAPIDe 3 study, confirming that the oral bradykinin B2 receptor antagonist deucrictibant shows strong...